DUBLIN – Advanced Accelerator Applications SA (AAA) surpassed even its own expectations in a phase III trial of its lead therapy Lutathera (177-Lu-Dotatate), which was pitted against a double dose of Sandostatin LAR in patients with somatostatin receptor positive midgut neuro endocrine tumors (midgut NETs)